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Summary
The most effective means of preventing human immunodeficiency virus (HIV) infection is preventing exposure. The provision
of antiretroviral drugs to prevent HIV infection after unanticipated sexual or injection-drug–use exposure might be beneficial.
The U.S. Department of Health and Human Services (DHHS) Working Group on Nonoccupational Postexposure Prophylaxis
(nPEP) made the following recommendations for the United States. For persons seeking care <72 hours after nonoccupational
exposure to blood, genital secretions, or other potentially infectious body fluids of a person known to be HIV infected, when that
exposure represents a substantial risk for transmission, a 28-day course of highly active antiretroviral therapy (HAART) is recom-
mended. Antiretroviral medications should be initiated as soon as possible after exposure. For persons seeking care <72 hours after
nonoccupational exposure to blood, genital secretions, or other potentially infectious body fluids of a person of unknown HIV
status, when such exposure would represent a substantial risk for transmission if the source were HIV infected, no recommenda-
tions are made for the use of nPEP. Clinicians should evaluate risks and benefits of nPEP on a case-by-case basis. For persons with
exposure histories that represent no substantial risk for HIV transmission or who seek care >72 hours after exposure, DHHS does
not recommend the use of nPEP. Clinicians might consider prescribing nPEP for exposures conferring a serious risk for transmis-
sion, even if the person seeks care >72 hours after exposure if, in their judgment, the diminished potential benefit of nPEP
outweighs the risks for transmission and adverse events. For all exposures, other health risks resulting from the exposure should be
considered and prophylaxis administered when indicated. Risk-reduction counseling and indicated intervention services should
be provided to reduce the risk for recurrent exposures.
Introduction
The most effective methods for preventing human immu-
nodeficiency virus (HIV) infection are those that protect
against exposure to HIV. Antiretroviral therapy cannot replace
behaviors that help avoid HIV exposure (e.g., sexual absti-
nence, sex only in a mutually monogamous relationship with
a noninfected partner, consistent and correct condom use,
abstinence from injection-drug use, and consistent use of sterile
equipment by those unable to cease injection-drug use). Medi-
The material presented in this report originated in the Division of
HIV/AIDS Prevention, National Center for HIV, STD, and TB
Prevention, Janet L. Collins, MD, Acting Director.
Corresponding Author:  Lisa A. Grohskopf, MD, Epidemiology
Branch, Division of HIV/AIDS Prevention, National Center for HIV,
STD and TB Prevention, CDC, 1600 Clifton Road NE, MS-E45,
Atlanta, GA 30333. Telephone: 404-639-6116; Fax: 404-639-6127;
e-mail: lkg6@cdc.gov.
2 MMWR January 21, 2005
cal treatment after sexual, injection-drug–use, or other non-
occupational HIV exposure* is less effective than preventing
HIV infection by avoiding exposure.
In July 1997, CDC sponsored the External Consultants
Meeting on Antiretroviral Therapy for Potential Nonoccupa-
tional Exposures to HIV. This panel of scientists, public health
specialists, clinicians, ethicists, members of affected communi-
ties, and representatives from professional associations and
industry evaluated the available evidence related to use of
antiretroviral medications after nonoccupational HIV exposure.
In 1998, DHHS issued a statement that outlined the available
information and concluded that evidence was insufficient about
the efficacy of nonoccupational postexposure prophylaxis
(nPEP) to recommend either for or against its use (1).
Since 1998, additional data about the potential efficacy of
nPEP have accumulated from human, animal, and laboratory
studies. Clinicians and organizations have begun providing
nPEP to patients they believe might benefit. In certain
instances, health departments have issued advisories or rec-
ommendations or otherwise supported the establishment of
nPEP treatment programs in their jurisdictions (2–6). In May
2001, CDC convened the second external consultants meet-
ing on nonoccupational post-exposure prophylaxis to review
and discuss the available data. This report summarizes knowl-
edge about the use and potential efficacy of nPEP and details
guidelines for its use in the United States.† The recommenda-
tions are intended for nonoccupational exposures and are not
applicable for occupational exposures.
Evidence of Possible Benefits
from nPEP
For ethical and logistical reasons, a randomized, placebo-
controlled clinical trial of nPEP probably will not be per-
formed. However, data are available from animal transmission
models, perinatal clinical trials, studies of health-care workers
receiving prophylaxis after occupational exposures, and from
observational studies. These data indicate that nPEP might
sometimes reduce the risk for HIV infection after nonoccu-
pational exposures.
Animal Studies
Animal studies have demonstrated mixed results (1,7). In
macaques, PMPA (tenofovir) blocked simian immunodefi-
ciency virus (SIV) infection after intravenous challenge if
administered within 24 hours of exposure and continued for
28 days. PMPA was not as effective if initiated 48 or 72 hours
postexposure or if continued for only 3 or 10 days (8). Two
macaque studies of combination antiretroviral therapy
(zidovudine, lamivudine, and indinavir) initiated 4 hours
after simian/human immunodeficiency virus (SHIV) challenge
and continued for 28 days did not protect against infection
but did result in reduced viral load among the animals
infected (9). In a macaque study designed to model nPEP for
mucosal HIV exposure, all animals administered PMPA for
28 days, beginning 12 hours (four animals) or 36 hours (four
animals) after vaginal HIV-2 exposure, were protected. Three
of four animals treated 72 hours after exposure were also pro-
tected; the fourth animal had delayed seroconversion and
maintained a low viral load after treatment (10).
These findings are consistent with those of macaque studies
of the biology of vaginal SIV transmission. After atraumatic
vaginal inoculation, lamina propria cells of the cervicovaginal
subepithelium were infected first, virus was present in drain-
ing lymph nodes within 2 days, and virus was disseminated to
the blood stream by 5 days (11). Similarly, in another study,
SIV-RNA was detected in dendritic cells from the vaginal epi-
thelium within 1 hour of intravaginal viral exposure, and SIV-
infected cells were detected in the lymph nodes within 18
hours (12). These data indicate a small window of opportu-
nity during which it might be possible to interrupt either the
initial infection of cells in the cervicovaginal mucosa or the
dissemination of local infection by the prompt administra-
tion of antiretroviral medications.
Postnatal Prophylaxis
Abbreviated regimens for reducing mother-to-child HIV
transmission have been studied extensively. Certain regimens
have included a postexposure component (antiretroviral medi-
cations given to the neonate). Although reduction in mater-
nal viral load during late pregnancy, labor, and delivery seems
to be a major factor in the effectiveness of these regimens, an
additional effect is believed to occur because the neonate
receives prophylaxis, which protects against infection from
exposure to maternal HIV during labor and delivery (13,14).
In a Ugandan perinatal trial, the rate of transmission at 14–16
weeks postpartum was substantially lower for women who
received a single dose of nevirapine at the beginning of labor
followed by a single dose of nevirapine to the neonate within
* In this report, a nonoccupational exposure is any direct mucosal,
percutaneous, or intravenous contact with potentially infectious body fluids
that occurs outside perinatal or occupational situations (e.g., health-care,
sanitation, public safety, or laboratory employment). Potentially infectious
body fluids are blood, semen, vaginal secretions, rectal secretions, breast milk
or other body fluid that is contaminated with visible blood.
† Information included in these recommendations might not represent Food
and Drug Administration (FDA) approval or approved labeling for the
particular products or indications in question. Specifically, the terms safe
and effective might not be synonymous with the FDA-defined legal standards
for product approval.
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72 hours of birth (transmission rate: 13.1%) than for the
women who received intrapartum zidovudine followed by 1
week of zidovudine to the neonate (transmission rate: 25.1%)
(15). Similarly low transmission rates were noted in a study in
South Africa in which intrapartum and postpartum
antiretroviral medications were used. At 8 weeks postpartum,
the transmission rate was 9.3% after intrapartum zidovudine
and lamivudine followed by 1 week of zidovudine and
lamivudine to mother and neonate, and the transmission rate
was 12.3% after a single dose of nevirapine administered to
the mother during labor and then to the neonate within 72
hours of birth (16). Although these studies lacked control
groups, these dosing schedules could not have substantially
reduced HIV exposure of the neonate through reducing ma-
ternal viral load, demonstrating that a combination of pre-
exposure and postexposure prophylaxis for the neonate reduces
HIV transmission. A study in Malawi among women who
did not receive intrapartum antiretrovirals compared postna-
tal prophylaxis with single-dose nevirapine with and without
zidovudine for 1 week. The transmission rate at 6–8 weeks
was 7.7% among infants who received zidovudine plus
nevirapine compared with 12.1% among those who received
nevirapine alone (17). Although this study did not have a pla-
cebo or no-prophylaxis arm, the transmission rate for the
zidovudine-nevirapine arm compares favorably with the rate
of 21% at 4 weeks, noted in the placebo arm of a study of
zidovudine prophylaxis conducted in Cote d’Ivoire (18).
 Two observational studies with relatively limited numbers
documented a potential effect of postnatal zidovudine pro-
phylaxis alone (without intrapartum medication). A review
of medical records in New York indicated that zidovudine
monotherapy administered to the mother intrapartum or to
the infant within 72 hours of birth reduced perinatal trans-
mission >50%; initiating monotherapy for the infant >72
hours after birth was less effective (19). Similarly, an analysis
of births in the PACTS study demonstrated that zidovudine
administered to infants within 24 hours of birth, when moth-
ers had not been treated either antepartum or intrapartum,
compared with no treatment for mothers or infants, reduced
perinatal transmission by 48% (20).
Observational Studies of nPEP
The most direct evidence supporting the efficacy of
postexposure prophylaxis is a case-control study of needlestick
injuries to health-care workers. In this study, the prompt initia-
tion of zidovudine was associated with an 81% decrease in
the risk for acquiring HIV (21). Although analogous clinical
studies of nPEP have not been conducted, data are available
from observational studies and registries.
In a high-risk HIV incidence cohort in Brazil, nPEP
instruction and 4-day starter packs of zidovudine and
lamivudine were administered to 200 homosexual and bisexual
men. Men who began taking nPEP after a self-identified high-
risk exposure were evaluated within 96 hours; 92% met the
event eligibility criteria (clinician-defined high-risk exposure).
Seroincidence was 0.7 per 100 person-years (one sero-
conversion) among men who took nPEP and 4.1 per 100 per-
son-years among men who did not take nPEP (11
seroconversions) (22,23). Subsequent analysis of data from
patients who took nPEP and had been followed for a median
of 24.2 months indicated 11 seroconversions and a sero-
incidence of 2.9 per 100 person-years, compared with an
expected seroincidence of 3.1 per 100 person years, p>0.97)
(24). In a study of sexual assault survivors in Sao Paolo, Bra-
zil, women who sought care within 72 hours after exposure
were treated for 28 days with either zidovudine and lamivudine
(for those without mucosal trauma) or zidovudine, lamivudine,
and indinavir (for those with mucosal trauma or those sub-
jected to unprotected anal sex) for 28 days. Women were not
treated if they sought care >72 hours after assault, if the assail-
ant was HIV-negative, or if a condom was used and no
mucosal trauma was seen. Of 180 women treated, none
seroconverted. Of 145 women not treated, four (2.7%)
seroconverted (25). Although these studies demonstrate that
nPEP might reduce the risk for infection after sexual HIV
exposures, participants were not randomly assigned, and
sample sizes were too small for statistically significant conclu-
sions.
In a study of rape survivors in South Africa, of 480 initially
seronegative survivors begun on zidovudine and lamivudine
and followed up for at least 6 weeks, one woman seroconverted.
She had started taking medications 96 hours after the assault.
An additional woman, who sought treatment 12 days after
assault, was seronegative at that time but not offered nPEP. At
retesting 6 weeks after the assault, she had seroconverted and
had a positive polymerase chain reaction result (Personal com-
munication, A. Wulfsohn, MD, Sunninghill Hospital,
Gauteng, South Africa).
In a feasibility trial of nPEP conducted in San Francisco,
401 persons with eligible sexual and injection-drug–use
exposures were enrolled. No seroconversions were observed
among those who completed treatment, those who interrupted
treatment, or those who did not receive nPEP (26). In a study
in British Columbia of 590 persons who completed a course
of nPEP, no seroconversions were observed (27). In registries
from four countries (Australia, France, Switzerland, and the
United States), including approximately 2,000 nonoccupa-
tional exposure case reports, no confirmed seroconversions
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have been attributed to a failure of nPEP in approximately
350 nPEP-treated persons reported to have been exposed to
HIV-infected sources. However, the absence of seroconversions
might not be attributed to receipt of nPEP but rather to the
low per-act risk for infection and incomplete follow-up in the
registries.
Case Reports
In addition to these studies, two case reports are of note. In
one, a patient who received a transfusion of red blood cells
from a person subsequently determined to have early HIV
infection began taking combination PEP 1 week after trans-
fusion and continued for 9 months. The patient did not
become infected despite the high risk associated with the trans-
fusion of HIV-infected blood (28). In the other case, nPEP
was initiated 10 days after self-insemination with semen from
a homosexual man later determined to have early HIV infec-
tion. The woman did not become infected but did become
pregnant and gave birth to a healthy infant (29).
Although data from the studies and case reports do not pro-
vide definitive evidence of the efficacy of nPEP after sexual,
injection-drug–use, and other nonoccupational exposures to
HIV, the cumulative data demonstrate that antiretroviral
therapy initiated soon after exposure and continued for 28
days might reduce the risk for acquiring HIV.
Evidence of Possible Risks
from nPEP
Concerns about the potential risks from nPEP as a public
health intervention include possible decrease in risk-reduc-
tion behaviors resulting from a perception that postexposure
treatment is available, the occurrence of serious adverse
effects from antiretroviral treatment in otherwise healthy per-
sons, and potential selection for resistant virus (particularly if
adherence is poor during the nPEP course). Evidence indi-
cates that these theoretical risks might not be major prob-
lems.
Effects on Risk-Reduction Behaviors
The availability or use of nPEP might not lead to increases
in risk behavior. Of participants in the nPEP feasibility study
in San Francisco, 72% reported a decrease in risk behavior
over the next 12 months relative to baseline reported risk
behavior, 14% reported no change, and 14% reported an
increase (30). However, 17% of participants requested a sec-
ond course of nPEP during the year after the first course,
indicating that although participants did not increase risk
behaviors, a substantial proportion of the participants did not
eliminate risk behaviors. A similar proportion of participants
(14%) requested a second course of nPEP at the Fenway Clinic
in Boston (31). In the Brazil nPEP study of homosexual and
bisexual men followed up for a median of 24 months, all
groups, including those who elected to take nPEP, reported
decreases in risk behavior (24,32). Among highly educated
(75% with >4 years of college), predominantly white (74%)
homosexual men who completed a street-outreach interviewer-
administered survey in San Francisco, those who reported that
they were aware of the availability of nPEP did not report
more risk behavior than those who were not aware (33). In a
study of discordant heterosexual couples, none reported
decreased condom use because of the availability of nPEP (34).
Antiretroviral Side Effects and Toxicity
Initial concerns about severe side effects and toxicities have
been ameliorated by experience with health-care workers who
have taken PEP after occupational exposures. Of 492 health-
care workers reported to the occupational PEP registry, 63%
took at least three medications. Overall, 76% of workers who
received PEP and had 6 weeks of follow-up reported certain
symptoms (i.e., nausea [57%] and fatigue or malaise [38%]).
Only 8% of these workers had laboratory abnormalities, few
of which were serious and all of which resolved promptly at
the end of antiretroviral treatment (35). Six (1.3%) reported
severe adverse events, and four stopped taking PEP because of
them. Of 68 workers who stopped taking PEP despite expo-
sure to a source person known to be HIV-positive, 29 (43%)
stopped because of side effects. According to the U.S. nPEP
surveillance registry, among 107 exposures for which nPEP
was taken, the regimen initially prescribed was stopped or
modified in 22%; modifications or stops were reported
because of side effects in half of these instances (36). In addi-
tion to reports in these registries, serious side effects have been
reported (e.g., nephrolithiasis and hepatitis) in the literature.
 During 1997–2000, a total of 22 severe adverse events in
persons who had taken nevirapine-containing regimens for
occupational or nonoccupational postexposure prophylaxis
were reported to FDA (37–38). Severe hepatotoxicity occurred
in 12 (one requiring liver transplantation), severe skin reac-
tions in 14, and both hepatic and cutaneous manifestations
occurred in four. Because the majority of occupational expo-
sures do not lead to HIV infection, the risk for using a
nevirapine-containing regimen for occupational PEP out-
weighs the potential benefits. The same rationale indicates that
nevirapine should not be used for nPEP.
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Selection of Resistant Virus
Antiretroviral PEP does not prevent all infections in occu-
pational and perinatal settings. Similarly, PEP is not expected
to have complete efficacy after nonoccupational exposures. In
instances where nPEP fails to prevent infection, selection of
resistant virus by the antiretroviral drugs is theoretically pos-
sible. However, because of the relative paucity of documented
nPEP failures for which resistance testing was performed, the
likelihood of this occurring is unknown.
 PEP failures have been documented after at least one sexual
(39) and 21 occupational (38,40) exposures. Three fourths of
these patients were treated with zidovudine monotherapy. Only
three received three or more antiretroviral medications for PEP.
Among the patients tested, several were infected with strains
that were resistant to antiretroviral medications. In a study in
Brazil (24), virus obtained on day 28 of therapy from the only
treated person who seroconverted (whose regimen included
3TC) had a 3TC-resistance mutation. However, the source-
person could not be tested. Therefore, whether the mutation
was present when the virus was transmitted or whether it
developed during nPEP could not be determined.
 Selection of resistant virus might occasionally result from
the use of nPEP. However, because the majority of nonoccu-
pational exposures do not lead to HIV infection and because
the use of combination antiretroviral therapy might reduce
further the transmission rate, such occurrences are probably
rare. For patients who seroconvert despite nPEP, resistance
testing should be considered to guide early and subsequent
treatment decisions.
Cost-Effectiveness of nPEP
Although the potential benefits of nPEP to persons are
measured by balancing its anticipated efficacy after a given
exposure against individual health risks, the value of nPEP as
a public health intervention is best addressed at the popula-
tion level by using techniques such as cost-benefit analysis.
Such analyses have been published. One cost-effectiveness
evaluation of nPEP in different potential exposure scenarios
in the United States reported it to be cost-effective only in
situations in which the sex partner source was known to be
HIV-infected or after unprotected receptive anal intercourse
with a homosexual or bisexual man of unknown serostatus
(41,42). A similar analysis in France reported that nPEP was
cost-saving for unprotected receptive anal intercourse with a
partner known to be HIV-infected and cost-effective for
receptive anal intercourse with a homosexual or bisexual part-
ner of unknown serostatus. It was not cost-effective for penile-
vaginal sex, insertive anal intercourse, or other exposures con-
sidered (43).
Another study and anecdotal reports indicate difficulty lim-
iting nPEP to the exposures most likely to benefit from it. In
British Columbia, where guidelines for nPEP use have been
implemented (5), an analysis indicated that >50% of those
receiving nPEP should not, according to the guidelines, have
been treated (e.g., for exposure to intact skin). The use of
nPEP in these circumstances doubled the estimated cost per
HIV infection prevented ($530,000 versus $230,000) (44).
Even if nPEP is cost-effective for the highest risk exposures,
behavioral interventions are more cost-effective (41,45). This
emphasizes the importance, when considering nPEP, of pro-
viding risk-avoidance and risk-reduction counseling to reduce
the occurrence of future HIV exposures.
Evidence of Current Practice
Although 40,000 new HIV infections occur in the United
States each year, relatively few exposed persons seek care after
nonoccupational exposure. Certain exposures are unrecog-
nized. Certain patients have frequently recurring exposures
and would not benefit from nPEP because 4 weeks of poten-
tial protection cannot substantially reduce their overall risk
for acquiring HIV infection. In addition, certain clinicians
and exposed patients are unaware of the availability of nPEP
or unconvinced of its efficacy and safety. Finally, access to
knowledgeable clinicians or a means of paying for nPEP might
constrain its use.
Certain populations in the United States remain at high
risk for exposure. In a cohort study of homosexual and
bisexual men, 17% reported at least one condom failure dur-
ing the 6 months preceding study enrollment (46). Other stud-
ies indicate that increasing use of highly active antiretroviral
therapy (HAART) by HIV-infected persons might be leading
some persons to have unprotected sex more frequently, in part
because of the belief that lowered viral load substantially
reduces infectivity (47–50). This finding is supported by
increased rates of sexually transmitted infections among
HIV-infected patients (51). In a California study, 69% of dis-
cordant heterosexual couples reported having had unprotected
sex during the preceding 6 months (34).
Since 1998, certain clinicians have recommended wider
availability and use of nPEP (52–58), and others have been
more cautious about implementing it in the absence of
definitive evidence of efficacy (59,60). Multiple public health
jurisdictions, including the New York State AIDS Institute,
the San Francisco County Health Department, the Massa-
chusetts Department of Public Health, the Rhode Island
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Department of Health, and the California State Office of
AIDS, have issued policies or advisories for nPEP use. Some
of these recommendations have focused on sexual assault sur-
vivors, who constitute few of the estimated 40,000 new HIV
infections annually in the United States.
Surveys of clinicians and facilities indicate a need for more
widespread implementation of guidelines and protocols for
nPEP use (61). In a survey of Massachusetts emergency
department directors, 52% of facilities had received nPEP
requests during the preceding year, but only 15% had written
nPEP protocols (62). Similarly, in a survey of Massachusetts
clinicians, approximately 20% had a written nPEP protocol
(63). Among pediatric emergency medicine specialists surveyed
throughout the United States and Canada, approximately 20%
had a written policy about nPEP use, but 33% had prescribed
it for children and adolescents; different prescribing practices
were reported (64). In a survey of 27 European Union coun-
tries, 23 had guidelines for occupational PEP use, but only six
had guidelines for nPEP use (65).
Evidence indicates considerable awareness of nPEP and
interest in its use among potential patients. In a cohort study
of homosexual and bisexual men, 60% were willing to par-
ticipate in a study of nPEP if it involved a single daily dose of
medication; 30% were willing to take 3 doses daily (66).
Among men surveyed at a “gay pride” festival in Atlanta,
although only 3% had used nPEP, 26% planned to if exposed
in the future (67). When nPEP studies were established in
San Francisco, approximately 400 persons sought treatment
in 2½ years (24). At a clinic primarily serving homosexual
and bisexual men in Boston, 71 requests for nPEP were evalu-
ated in 1½ years (30). In a California study of heterosexual
discordant couples, 28% had heard of nPEP, 55% of serone-
gative partners believed that it was effective, and 78% reported
they would take it if exposed (34).
No nationally representative data exists on nPEP use in the
United States. In 1998, CDC established a national nPEP
surveillance registry that accepts voluntary reports by clini-
cians. Although approximately 800 reports have been received,
the majority of clinicians prescribing nPEP do not report to
the registry. Similarly, low reporting rates were obtained in
attempts to establish voluntary registries to monitor occupa-
tional PEP and antiretroviral use during pregnancy. No
national surveys of clinicians have been reported. However,
one multisite HIV vaccine trial largely conducted in the United
States has assessed nPEP use by 5,418 participants, who
included men who have sex with men (94%) and heterosexual
women at high risk (6%). Two percent of trial participants
from 27 study sites reported having taken nPEP during the
trial. Supplementary data from six U.S. sites indicated that
46% of participants had heard of nPEP. Enrollment at one of
seven California sites (odds ratio [OR] = 3.2), having a known
positive partner (OR = 2.0), higher educational level (OR =
1.4), and greater recreational drug use (OR = 1.2) were sig-
nificant predictors of having used nPEP (p<0.05) (68).
Evaluation of Persons Seeking Care
After Potential Nonoccupational
Exposure to HIV
The effective delivery of nPEP after exposures that have a
substantial risk for HIV infection requires prompt evaluation
of patients and consideration of biomedical and behavioral
interventions to address current and ongoing health risks. This
evaluation should include determination of the HIV status of
the potentially exposed person, the timing and characteristics
of the most recent exposure, the frequency of exposures to
HIV, the HIV status of the source, and the likelihood of con-
comitant infection with other pathogens or negative health
consequences of the exposure event.
HIV Status of the Potentially Exposed
Person
Because persons who are infected with HIV might not be
aware they are infected, baseline HIV testing should be per-
formed on all persons seeking evaluation for potential nonoc-
cupational HIV exposure. If possible, this should be done with
an FDA-approved rapid test kit (with results available within
an hour). If rapid tests are not available, an initial treatment
decision should be made based on the assumption that the
potentially exposed patient is not infected, pending HIV test
results.
Timing and Frequency of Exposure
Available data indicate that nPEP is less likely to be effec-
tive if initiated >72 hours after HIV exposure. If initiation of
nPEP is delayed, the likelihood of benefit might not outweigh
the risks inherent in taking antiretroviral medications.
 Because nPEP is not 100% effective in preventing trans-
mission and because antiretroviral medications carry a certain
risk for adverse effects and serious toxicities, nPEP should be
used only for infrequent exposures. Persons who engage in
behaviors that result in frequent, recurrent exposures that
would require sequential or near-continuous courses of
antiretroviral medications (e.g., discordant sex partners who
rarely use condoms or injection-drug users who often share
injection equipment) should not take nPEP. In these instances,
exposed persons should instead be provided with intensive
risk-reduction interventions.
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HIV Status of Source
Patients who have had sexual, injection-drug–use, or other
nonoccupational exposures to potentially infectious fluids of
persons known to be HIV infected are at risk for acquiring
HIV infection and should be considered for nPEP if they seek
treatment within 72 hours of exposure. If possible, source
persons should be interviewed to determine his or her history
of antiretroviral use and most recent viral load because this
information might provide information for the choice of nPEP
medications.
Persons with exposures to potentially infectious fluids of
persons of unknown HIV status might or might not be at risk
for acquiring HIV infection. When the source is known to be
from a group with a high prevalence of HIV infection (e.g., a
homosexual or bisexual man, an injection–drug user, or a com-
mercial sex worker), the risk for transmission might be
increased. The risk for transmission might be especially great
if the source person has been infected recently, when viral bur-
den in blood and semen might be particularly high (69,70).
However, ascertaining this in the short time available for nPEP
evaluation is rarely possible. When the HIV status of the source
is unknown, it should be determined whether the source is
available for HIV testing. If the risk associated with the expo-
sure is considered substantial, nPEP can be started pending
determination of the HIV status of the source and then stopped
if the source is determined to be noninfected.
Transmission Risk from the Exposure
Although the estimated per-act transmission risk from
unprotected exposure to a partner known to be HIV infected
is relatively low for different types of exposure (Table 1), dif-
ferent nonoccupational exposures are associated with differ-
ent levels of risk (71–79). The highest levels of estimated per-act
risk for HIV transmission are associated with blood transfu-
sion, needle sharing by injection-drug users, receptive anal
intercourse, and percutaneous needlestick injuries. Insertive
anal intercourse, penile-vaginal exposures, and oral sex repre-
sent substantially less per-act risk.
A history should be taken of the specific sexual, injection-
drug–use, or other behaviors that might have led to, or modi-
fied, a risk for acquiring HIV infection. Eliciting a complete
description of the exposure and information about the HIV
status of the partner(s) can substantially lower (e.g., if the
patient was the insertive partner or a condom was used) or
increase (e.g., if the partner is known to be HIV-positive) the
estimate of risk for HIV transmission resulting from a specific
exposure.
In addition to sexual and injection-drug–use exposures,
percutaneous injuries from needles discarded in public set-
tings (e.g., parks and buses) result in requests for nPEP with a
certain frequency. Although no HIV infections from such
injuries have been documented, concern exists that syringes
discarded by injection-drug users (e.g., for whom the HIV
infection rate is higher than that for diabetics) might pose a
substantial risk. However, these injuries typically involve small-
bore needles that contain only limited amounts of blood, and
the viability of any virus present is limited. In a study of
syringes used to administer medications to HIV-infected per-
sons, only 3.8% had detectable HIV RNA (72). In a study of
the viability of virus in needles, viable virus was recovered
from 8% at 21 days when the needles had been stored at room
temperature; <1% had viable virus after 1 week of storage at
higher temperatures (73).
Bite injuries represent another potential means of transmit-
ting HIV. However, HIV transmission by this route has been
reported rarely (80-82). Transmission might theoretically
occur either though biting or receiving a bite from an HIV-
infected person. Biting an HIV-infected person, resulting in a
break in the skin, exposes the oral mucous membranes to
infected blood; being bitten by an HIV-infected person
exposes nonintact skin to saliva. Saliva that is contaminated
with infected blood poses a substantial exposure risk. Saliva
that is not contaminated with blood contains HIV in much




Evaluation for sexually transmitted infections is important
because these infections might increase the risk for acquiring
HIV infection from a sexual exposure. In 1996, an estimated
5,042 new HIV infections were attributable to sexually trans-
mitted infection at the time of HIV exposure (84). In addi-




Exposure route  to an infected source Reference
Blood transfusion 9,000 74
Needle-sharing injection-drug use 67 75
Receptive anal intercourse 50 76, 77
Percutaneous needle stick 30 78
Receptive penile-vaginal intercourse 10 76, 77, 79
Insertive anal intercourse 6.5 76, 77
Insertive penile-vaginal intercourse  5 76, 77
Receptive oral intercourse 1 77†
Insertive oral intercourse 0.5 77†
* Estimates of risk for transmission from sexual exposures assume no
condom use.
†Source refers to oral intercourse performed on a man.
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tion, any sexual exposure that presents a risk for HIV infec-
tion might also place a patient at risk for acquiring other sexu-
ally transmitted infections, including hepatitis B. Prophylaxis
for sexually transmitted disease, testing for hepatitis, and vac-
cination for hepatitis B (for those not immune) should be
considered (85).
For women of reproductive capacity who have had genital
exposure to semen, the risk for pregnancy also exists. In these
instances, emergency contraception should be discussed with
the potentially exposed patient.
Recommendations for Use
of Antiretroviral nPEP
A 28-day course of HAART is recommended for persons
who have had nonoccupational exposure to blood, genital
secretions, or other potentially infected body fluids of a per-
sons known to be HIV infected when that exposure repre-
sents a substantial risk for HIV transmission (Figure 1) and
when the person seeks care within 72 hours of exposure. When
indicated, antiretroviral nPEP should be initiated promptly
for the best chance of success.
Evidence from animal studies and human observational stud-
ies demonstrate that nPEP administered within 48–72 hours
and continued for 28 days might reduce the risk for acquiring
HIV infection after mucosal and other nonoccupational
exposures. The sooner nPEP is administered after exposure,
the more likely it is to interrupt transmission. Because HIV is
an incurable transmissible infection that affects the quality
and duration of life, HAART should be used to maximally
suppress local viral replication that otherwise might occur in
the days after exposure and potentially lead to a disseminated,
established infection (11,86). One of the HAART combina-
tions recommended for the treatment of persons with estab-
lished HIV infection should be selected on the basis of
adherence, toxicity, and cost considerations (Tables 2 and 3)
(87,88).
No evidence indicates that any specific antiretroviral medica-
tion or combination of medications is optimal for use as nPEP.
However, on the basis of the degree of experience with indi-
vidual agents in the treatment of HIV-infected persons, certain
agents and combinations are preferred. Preferred regimens
include efavirenz and lamivudine or emtricitabine with
zidovudine or tenofovir (as a nonnucleoside-based regimen) and
lopinavir/ritonavir (coformulated in one tablet as Kaletra®) and
zidovudine with either lamivudine or emtricitabine. Different
alternative regimens are possible (Table 2).
No evidence indicates that a three-drug HAART regimen is
more likely to be effective than a two-drug regimen. The rec-
ommendation for a three-drug HAART regimen is based on
the assumption that the maximal suppression of viral replica-
tion afforded by HAART (the goal in treating HIV-infected
persons) will provide the best chance of preventing infection
in a person who has been exposed. Clinicians and patients
who are concerned about potential adherence and toxicity
issues associated with a three-drug HAART regimen might
consider the use of a two-drug regimen (i.e., a combination of
two reverse transcriptase inhibitors). Regardless of the regi-
men chosen, the exposed person should be counseled about
the potential associated side effects and adverse events that
require immediate medical attention. The use of medications
to treat symptoms (e.g., antiemetics or antimotility agents)
might improve adherence in certain instances.
Although certain preliminary studies have evaluated the
penetration of antiretroviral medications into genital tract
secretions and tissues (89,90), evidence is insufficient to rec-
ommend a specific antiretroviral medication as most effective
for nPEP. In addition, new antiretroviral medications might
become available. As new medications and new information
become available, these recommendations will be amended
and updated.
When the source-person is available for interview, his or
her history of antiretroviral medication use and most recent














vagina, rectum, eye, mouth,
or other mucous membrane,
nonintact skin, or percutaneous contact
blood, semen, vaginal secretions, rectal
secretions, breast milk, or any body fluid
that is visibly contaminated with blood
the source is known to be HIV-infected
Negligible Risk for HIV Exposure
Exposure of
vagina, rectum, eye, mouth,
or other mucous membrane,
intact or nonintact skin, or
percutaneous contact
urine, nasal secretions, saliva, sweat,
or tears if not visibly contaminated
with blood
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TABLE 2. Antiretroviral regimens for nonoccupational
postexposure prophylaxis of HIV infection
Preferred regimens
NNRTI*-based Efavirenz† plus (lamivudine or emtricitabine)
plus (zidovudine or tenofovir)
Protease inhibitor Lopinavir/ritonavir (co-formulated as
(PI)-based Kaletra) plus (lamivudine or emtricitabine)
plus zidovudine
Alternative regimens
NNRTI-based Efavirenz plus (lamivudine or emtricitabine)
plus abacavrir or didanosine  or stavudine§
PI-based Atazanavir plus (lamivudine or emtricitabine)
plus (zidovudine or stavudine or abacavir or
didanosine) or (tenofovir plus ritonavir
[100 mg/day])
Fosamprenavir plus (lamivudine or
emtricitabine) plus (zidovudine or stavudine) or
(abacavir or tenofovir or didanosine)
Fosamprenavir/ritonavir¶  plus (lamivudine or
emtricitabine) plus (zidovudine or stavudine or
abacavir or tenofovir or didanosine)
Indinavir/ritonavir¶** plus (lamivudine or
emtricitabine) plus (zidovudine or stavudine or
abacavir or tenofovir or didanosine)
Lopinavir/ritonavir (co-formulated as Kaletra)
plus (lamivudine or emtricitabine) plus
(stavudine or abacavir or tenofovir or idanosine)
Nelfinavir plus (lamivudine or emtricitabine)
plus (zidovudine or stavudine or abacavir or
tenofovir or didanosine)
Saquinavir (hgc* or sgc*)/ritonavir† plus
(lamivudine or emtricitabine) plus (zidovudine
or stavudine or abacavir or tenofovir or
didanosine)
Triple NRTI* Abacavir plus lamivudine plus zidovudine (only
when an NONRTI- or PI-based regimen
cannot or should not be used)
* NNRTI = non-nucleoside reverse transcriptase inhibitor; NRTI = nucleo-
side reverse transcriptase inhibitor; sgc = soft-gel saquinavir capsule
(Fortovase); hgc = hard-gel saquinavir capsule (Invirase).
† Efavirenz should be avoided in pregnant women and women of child-
bearing potential.
§ Higher incidence of lipoatrophy, hyoerlipidemia, and mitochondrial
toxicities associated with stavudine than with other NRTIs.
¶ Low-dose (100–400 mg) ritonavir. See Table 4 for doses used with
specific PIs.
** Use of ritonavir with indinavir might increase risk for renal adverse events.
Source: U.S. Department of Health and Human Services. Guidelines for
the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents,
October 29,2004 revision. Available at http://www.aidsinfo.nih.gov/guide-
lines/default_db2.asp?id=50. This document is updated periodically; refer
to website for updated versions.
viral load measurement should be considered when selecting
antiretroviral medications for nPEP. This information might
help avoid prescribing antiretroviral medications to which the
source-virus is likely to be resistant. If the source-person is
willing, the clinician might consider drawing blood for viral
load and resistance testing, the results of which might be use-
ful in modifying the initial nPEP medications if the results
can be obtained promptly (91).
For persons who have had nonoccupational exposure to
potentially infected body fluids of a person of unknown HIV
infection status, when that exposure represents a substantial
risk for HIV transmission (Figure 1) and when care is sought
within 72 hours of exposure, no recommendations are made
either for or against the use of antiretroviral nPEP. Clinicians
should evaluate the risk for and benefits of this intervention
on a case-by-case basis.
When a source-person is not known to be infected with
HIV, the risk for exposure (and therefore the potential benefit
of nPEP) is unknown. Prescribing antiretroviral medication
in these cases might subject patients to risks that are not bal-
anced with the potential benefit of preventing the acquisition
of HIV infection. Judging whether the balance is appropriate
depends entirely on the circumstances of the possible expo-
sure (i.e., the risk that the source is HIV infected and the risk
for transmission if the source is HIV infected) and is best de-
termined through discussion between the clinician and the
patient.
If the source-person is available for interview, additional
information about risk history can be obtained and permis-
sion for an HIV test requested to assist in determining the
likelihood of HIV exposure. When available, FDA-approved
rapid HIV tests are preferable for obtaining this information
as quickly as possible. These additional factors might assist in
the decision whether to start or complete a course of nPEP. If
data to clearly determine risk are not immediately available,
clinicians might consider initiating nPEP while further
assessments are being made and then stopping it when other
information is available (e.g., the source-person is determined
to be noninfected).
For persons whose exposure histories represent no substan-
tial risk for HIV transmission (Figure 1) or who seek care >72
hours after potential nonoccupational HIV exposure, the use
of antiretroviral nPEP is not recommended. When the risk
for HIV transmission is negligible, limited benefit is antici-
pated from the use of nPEP. In addition, animal and human
study data demonstrate that nPEP is less likely to prevent HIV
transmission when initiated >72 hours after exposure. Because
the risks associated with antiretroviral medications are likely
to outweigh the potential benefit of nPEP in these circum-
stances, nPEP is not recommended for such exposures,
regardless of the HIV status of the source. However, it cannot
be concluded on the basis of the available data that nPEP will
be completely ineffective when initiated >72 hours after
exposure. Moreover, data do not indicate an absolute time
after exposure beyond which nPEP will not be effective. When
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TABLE 3. Highly active antiretroviral therapy medications, adult dosage, cost, and side effects
Cost (in dollars)
Medication Adult dosage* for 4 weeks† Side effects and toxicities
Combination tablets
Lopinavir/ritonavir (Kaletra®) § 3 tablets twice daily 650 Diarrhea, nausea, vomiting; asthenia;
400 mg lopinavir/100 mg ritonavir elevated transaminases; hyperglycemia;
fat redistribution; lipid abnormalities;
possible increased bleeding in persons
with hemophilia; and pancreatitis
Zidovudine/lamivudine (Combivir®) 1 tablet twice daily 640 See following individual medications
300 mg zidovudine/150 mg lamivudine
Zidovudine/lamivudine/abacavir (Trizivir®) 1 tablet twice daily 1,020 See following individual medications
300 mg zidovudine/150 mg lamivudine/
300 mg abacavir
Lamivudine/abacavir (Epzicom®) 1 tablet once daily 760 See following individual medications
300 mg  lamivudine/600 mg abacavir
Emtricitabine/tenofovir (Truvada®) 1 tablet once daily 800 See following individual medications
200 mg emtricitabine/300 mg tenofovir
Single agents
Nucleoside and nucleotide reverse
transcriptase inhibitors
(Side effects as a class: lactic acidosis,
severe hepatomegaly with steatosis,
including some fatal cases)
Abacavir (Ziagen®, ABC)§ 300 mg twice daily or 600 mg once daily 400 Severe hypersensitivity reaction
(can be fatal); nausea; and vomiting
Didanosine (Videx®, ddI)§ >60 kg (132 lb) body weight: 200 mg 260 Pancreatitis; nausea, diarrhea; and
twice daily or 400 mg daily; if with tenofovir, peripheral neuropathy
250 mg/daily
<60 kg (132 lb): 125 mg twice daily
or 250 mg daily; if with tenofovir, dose
not established
Do not use with stavudine (d4T, Zerit)
during pregnancy; avoid ddI/d4T
combination in general because of increased
risk for adverse events (e.g., neuropathy,
pancreatitis, and hyperlactatemia)
Emtricitabine (Emtriva®, FTC) 200 mg once daily 280 Minimal toxicity; lactic acidosis and
hepatic steatosis a rare but possibly life-
threatening event
Lamivudine (Epivir®, 3TC)§ 150 mg twice daily or 300 mg once daily 300 Minimal toxicity; lactic acidosis and
hepatic steatosis a rare but possibly
life-threatening event
Stavudine (Zerit®, d4T)§ >60 kg (132 lb) body weight: 320 Pancreatitis; peripheral neuropathy;
40 mg twice daily rapidly progressive ascending
neuromuscular weakness (rare)
<60 kg (132 lb) body weight:
30 mg twice daily
Do not use with didanosine (ddI, Videx)
during pregnancy; avoid ddI/d4T combination
in general because of increased risk for
adverse events (e.g., neuropathy, pancreatitis,
and hyperlactatemia)
Tenofovir (Viread®) 300 mg daily 400 Nausea, vomiting, diarrhea; headache;
asthenia; flatulence; and renal
impairment
Zidovudine (Retrovir®, AZT)§ 200 mg three times daily 350 Bone marrow suppression (anemia,
or 300 mg twice daily neutropenia); gastrointestinal
intolerance; headache; insomnia;
asthenia; and myopathy
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Single agents
Non-nucleoside reverse transcriptase
inhibitors (Side effects as a class:
Stevens-Johnson syndrome)
Efavirenz (Sustiva®) 600 mg daily at bedtime 420 Rash; central nervous system symptoms
Do not use during known (e.g., dizziness, impaired concentration,
or possible pregnancy insomnia, and abnormal dreams);
transaminase elevation; and false-
positive cannabinoid test
Protease inhibitors
(Side effects as a class: gastrointestinal
intolerance, hyperlipidemia, hyperglycemia,
diabetes, fat redistribution, and possible
increased bleeding in hemophiliacs)
Atazanavir (Reyataz®) 400 mg once daily; if administered 760 Indirect hyperbilirubinemia; prolonged
with tenofovir plus ritonavir, 300 mg PR interval (use caution in patients with
once daily underlying cardiac conduction defects or
on concomitant medications that can
cause PR prolongation)
Fosamprenavir (Lexiva®)§ 1,400 mg twice daily 1,260 Gastrointestinal intolerance, nausea,
vomiting, diarrhea; rash; elevated
transaminases; and headache
Indinavir (Crixivan®) 800 mg every 8 hours 500 Gastrointestinal intolerance, nausea;
With ritonavir (might increase risk nephrolithiasis; headache; asthenia;
for renal adverse events): blurred vision; metallic taste;
800 mg indinavir and thrombocytopenia; hemolytic anemia;
100 mg ritonavir every 12 hours and indirect hyperbilirubinemia
or (inconsequential)
800 mg indinavir and
200 mg ritonavir every 12 hours
Nelfinavir (Viracept®)§ 750 mg three times daily or 600 Diarrhea; and elevated transaminases
1,250 mg twice daily
Ritonavir (Norvir®)§ See doses used in combination 700–2,800 Gastrointestinal intolerance; nausea,
with other specific protease inhibitors vomiting, diarrhea; paresthesias;
hepatitis; panreatitis; asthenia; and taste
perversion;  many drug interactions
Saquinavir (hard-gel capsule) With ritonavir: 270 Gastrointestinal intolerance; nausea,
(Invirase®) 400 mg saquinavir and diarrhea; headache; and elevated
400 mg ritonavir twice daily transaminases
or
1,000 mg saquinavir and
100 mg ritonavir twice daily
Saquinavir (soft-gel capsule) With Ritonavir: 460 Gastrointestinal intolerance; nausea,
(Fortavase®) 400 mg saquinavir and diarrhea; abdominal pain; dyspepsia;
400 mg ritonavir twice daily headache; and elevated transaminases
or
1,000 mg saquinavir and
100 mg ritonavir twice daily




Sources: U.S. Department of Health and Human Services and the Henry J.Kaiser Family Foundation. Guidelines for the use of antiretroviral agents in HIV-
infected adults and adolescents. Available at http://www.aidsinfo.nih.gov/guidelines/default_db2.asp?id=50 (refer to website for updated versions). Bartlett
JG, Finkbeiner AK. HIV drugs: the guide to living with HIV infection. 2001. 11-13-2001. Available at http://www.thebody.com/jh/bartlett/drugs.html.
TABLE 3. (Continued) Highly active antiretroviral therapy medications, adult dosage, cost, and side effects
Cost (in dollars)
Medication Adult dosage* for 4 weeks† Side effects and toxicities
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safer and more tolerable drugs are used, the risk-benefit ratio
of providing nPEP >72 hours postexposure is more favorable.
Therefore, clinicians might consider prescribing nPEP after
exposures that confer a serious risk for transmission, even if
the exposed person seeks care >72 hours postexposure if, in
the clinician’s judgment, the diminished potential benefit of
nPEP outweighs the potential risk for adverse events from
antiretroviral drugs.
Considerations for All Patients
Treated with Antiretroviral nPEP
Use of Starter Packs
Patients might be under considerable emotional stress when
seeking care after a potential HIV exposure and might not
attend to, or retain, all the information relevant to making a
decision about nPEP. Clinicians should give an initial pre-
scription for 3–5 days of medication and schedule a follow-
up visit to review the results of baseline HIV testing (if rapid
tests are not used), provide additional counseling and sup-
port, assess medication side effects and adherence, and pro-
vide additional medication if appropriate (with an altered
regimen if indicated by side effects or laboratory test results).
Scientific Consultation
When clinicians are not experienced with using HAART or
when information from source-persons indicates the possibil-
ity of antiretroviral resistance, consultation with infectious
disease or other HIV-care specialists, if it is available immedi-
ately, might be warranted before prescribing nPEP. Similarly,
when considering prescribing nPEP to pregnant women or
children, consultation with obstetricians or pediatricians might
be advisable. However, if such consultation is not immedi-
ately available, initiation of nPEP should not be delayed. An
initial nPEP regimen should be started and, if necessary,
revised after consultation is obtained. Patients who seek nPEP
might benefit from referral for psychological counseling that
helps ease the anxiety about possible HIV exposure, strength-
ens risk-reduction behaviors, and promotes adherence to nPEP
regimens if prescribed.
Facilitating Adherence
Adherence to antiretroviral medications can be challeng-
ing, even for 28 days. In addition to common side effects such
as nausea and fatigue, each dose reminds the patient of his or
her risk for acquiring HIV infection. Adherence has been
reported to be especially poor among sexual assault survivors
(92–96). Steps to maximize medication adherence include
prescribing medications with fewer doses and fewer pills per
dose, educating patients about the importance of adherence
and about potential side effects, offering ancillary medications
for side effects (e.g., anti-emetics) if they occur, and provid-
ing access to ongoing encouragement and consultation by
phone or office visit.
Follow-up Testing and Care
All patients seeking care after HIV exposure should be tested
for the presence of HIV antibodies at baseline and at 4–6
weeks, 3 months, and 6 months after exposure to determine
whether HIV infection has occurred. In addition, testing for
sexually transmitted diseases, hepatitis B and C, and preg-
nancy should be offered (Table 4).
Patients should be instructed about the signs and symp-
toms associated with acute retroviral infection (Table 5),
especially fever and rash (97), and asked to return for evalua-
tion if these occur during or after nPEP. Acute HIV infection
is associated with high viral loads. However, clinicians should
be aware that available assays might yield low viral-load
results (e.g., <3,000) in noninfected persons. Such false-
positive results can lead to misdiagnosis of HIV infection (98).
Transient, low-grade viremia has been observed both in
macaques exposed to SIV (99) and humans exposed to HIV
who were administered antiretroviral PEP (100) and did not
become infected. In certain cases, this outcome might repre-
sent aborted infection rather than false-positive test results,
but this can be determined only through further study. For
patients with clinical or laboratory evidence of acute HIV
infection, continuing antiretroviral therapy for >28 days might
be prudent because such early treatment (no longer prophy-
laxis) might slow the progression of HIV disease (101).
Patients with acute HIV infection should be transferred to
the care of HIV treatment specialists.
In addition, clinicians who provide nPEP should monitor
liver function, renal function, and hematologic parameters as
indicated by the prescribing information found in antiretroviral
treatment guidelines (87,102,103), package inserts, and the
Physician’s Desk Reference (Table 3). Unusual or severe toxici-
ties from antiretroviral drugs should be reported to the manu-
facturer or FDA.
HIV Prevention Counseling
The majority of persons who seek care after a possible HIV
exposure do so because of failure to initiate or maintain effec-
tive risk-reduction behaviors. Notable exceptions are sexual
assault survivors and children with community-acquired
needlestick injuries.
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Although nPEP might reduce the risk for HIV infection, it is
not believed to be 100% effective. Therefore, patients should
practice protective behaviors with sex partners (e.g., abstinence
or consistent use of male condoms) or drug-use partners (e.g.,
avoidance of shared injection equipment) throughout the course
of nPEP to avoid transmission to others if they become infected,
and after nPEP to avoid future HIV exposures.
At follow-up visits, clinicians should assess their patients’
needs for behavioral intervention, education, and services. This
assessment should include frank, nonjudgmental questions
about sexual behaviors, alcohol use, and illicit drug use. Cli-
nicians should help patients identify ongoing risk issues and
develop plans for improving their use of protective behaviors
(104).
To help patients obtain indicated interventions and services,
clinicians should be aware of local resources for high-quality
HIV education and ongoing behavioral risk reduction, coun-
seling and support, inpatient and outpatient alcohol and drug-
treatment services, substance/drug abuse treatment programs,
family and mental health counseling services, and support
programs for HIV-infected persons. Information about pub-
licly funded HIV prevention programs can be obtained from
state or local health departments.
Management of Source Persons
When source-persons are seen during the course of evaluat-
ing a patient for potential HIV exposure, clinicians should
also assess the source-person’s access to relevant medical care,
behavioral intervention, and social support services. If needed
care cannot be provided directly, clinicians should help source-
persons obtain care in the community.
If a new diagnosis of HIV infection is made or evidence of
other sexually transmitted infection is identified, the patient
TABLE 4. Recommended laboratory evaluation for nonoccupational postexposure prophylaxis (nPEP) of HIV infection
4–6 Weeks 3 Months 6 Months
Test Baseline During nPEP* after exposure after exposure after exposure
HIV antibody testing E†, S§ E E E
Complete blood count with differential E E
Serum liver enzymes E E
Blood urea nitrogen/creatinine E E
Sexually transmitted diseases screen E, S E¶ E¶
(gonorrhea, chlamydia, syphilis)
Hepatitis B serology E, S E¶ E¶
Hepatitis C serology E, S E E
Pregnancy test (for women of reproductive age) E E¶ E¶
HIV viral load S E** E** E**
HIV resistance testing S E** E** E**
CD4+T lymphocyte count S E** E** E**
* Other specific tests might be indicated dependent on the antiretrovirals prescribed. Literature pertaining to individual agents should be consulted.
† E = exposed patient, S = source.
§ HIV antibody testing of the source patient is indicated for sources of unknown serostatus.
¶ Additional testing for pregnancy, sexually transmitted diseases, and hepatitis B should be performed as clinically indicated.
** If determined to be HIV infected on follow-up testing; perform as clinically indicated once diagnosed.
TABLE 5. Expected frequency of associated signs and







Erythematous maculopapular with lesions on face,
trunk and sometimes extremities, including palms
and soles; mucocutaneous ulceration involving mouth,
esophagus or genitals
Myalgia or arthralgia 54
Diarrhea 32
Headache 32





Meningoencephalitis or aseptic meningitis;
peripheral neuropathy or radiculopathy;
facial palsy; Guillain-Barré syndrome;
brachial neuritis; or cognitive impairment or psychosis
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should be assisted in notifying their sexual and drug-use con-
tacts. Assistance with confidential partner notification (with-
out revealing the patient’s identity) is available through local
health departments.
Reporting and Confidentiality
Because of the emotional, social, and potential financial
consequences of possible HIV infection, clinicians should
handle nPEP evaluations with the highest level of confidenti-
ality. Confidential reporting of sexually transmitted infections
and newly diagnosed HIV infections to health departments
should take place as dictated by local law and regulations.
For cases of sexual assault, clinicians should document their
findings and assist patients with notifying local authorities.
HIV test results should be recorded separately from the find-
ings of the sexual assault examination to protect patients’ con-
fidentiality in the event that medical records are later released
for legal proceedings. Certain states and localities have special
programs to provide reimbursement for medical therapy,
including antiretroviral medication after sexual assault, and
these areas might have specific reporting requirements. When
the sexual abuse of a child is suspected or documented, the




Pregnant Women and Women
of Childbearing Potential
Considerable experience has been gained in recent years in
the safe and appropriate use of antiretroviral medications dur-
ing pregnancy, either for the benefit of the HIV-infected
woman’s health or to prevent transmission to newborns. To
facilitate the selection of antiretroviral medications likely to
be both effective and safe for the developing fetus, clinicians
should consult DHHS guidelines (102) before prescribing
nPEP for a woman who is or might be pregnant.
Because of potential teratogenicity, efavirenz should not be
used in any nPEP regimen during pregnancy or among women
of childbearing age at risk for becoming pregnant during the
course of antiretroviral prophylaxis (Table 3). A protease
inhibitor- or nucleoside reverse transcriptase inhibitor-based
regimen should be considered in these circumstances. When
efavirenz is prescribed to women of childbearing potential,
they should be instructed about the need to avoid pregnancy.
Because the effect of efavirenz on hormonal contraception is
unknown, women using such contraception should be
informed of the need to use an additional method (e.g., bar-
rier contraception). In addition, because of reports of mater-
nal and fetal mortality attributed to lactic acidosis associated
with prolonged use of d4T in combination with ddI in HIV-
infected pregnant women, this combination is not recom-
mended for use in an nPEP regimen (105).
Children
Potential HIV exposures in children occur most often by
accident (e.g., needlesticks in the community, fights, or play-
ground incidents resulting in bleeding by an HIV-infected
child) or by sexual abuse or assaults (106). In a review of charts
from 1 year in the pediatric emergency department of one
hospital, 10 children considered for nPEP were identified (six
because of sexual assault and four because of needlestick
injury). Eight began taking nPEP, but only two completed
the 4-week course (63,107). An analysis of 9,136 reported
acquired immunodeficiency syndrome cases in children iden-
tified 26 who were sexually abused with confirmed or sus-
pected exposure to HIV infection (108).
The American Academy of Pediatrics has issued nPEP guide-
lines for pediatric patients (109). In addition, DHHS pediat-
ric antiretroviral treatment guidelines (103) provide
information about the use of antiretroviral agents in children.
For young children who cannot swallow capsules or tablets
and to ensure appropriate dosing for drugs that do not have
capsule/tablet formulations that allow pediatric dosing, drugs
for which pediatric formulations are available might need to
be prescribed (Table 3). Adherence to the prescribed medica-
tions will depend on the involvement of, and support pro-
vided to, parents or guardians.
Sexual Assault Survivors
Use of nPEP for sexual assault survivors has been widely
encouraged both in the United States and elsewhere (56,
94,110,111). Sexual assault is relatively common among
women: 13% of a national sample of adult women reported
having ever been raped (60% before age 18), and 5% reported
having been raped more than once (112). Sexual assault is not
uncommon among men. In one series from an emergency
department, 5% of reported rapes involved men sexually
assaulted by men (113). Males accounted for 11.6 % of rapes
reported among persons aged >12 years who responded to the
National Crime Victimization Survey in 1999 (114). How-
ever, only three documented cases of HIV infection resulting
from sexual assault have been published (94,115,116). In
observational studies, HIV infections have been temporally
associated with sexual assault (Personal communication,
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A. Wulfsohn, MD, Sunninghill Hospital, Gauteng, South
Africa).
Studies have examined HIV infection rates for sexual assail-
ants (117,118). The largest of these, an evaluation of men
incarcerated in Rhode Island, determined that 1% of those
convicted of sexual assault were HIV infected when they
entered prison, compared with 3% of all prisoners and 0.3%
of the general male population (119).
 Sexual assault typically has multiple characteristics that
increase the risk for HIV transmission if the assailant is
infected. In one prospective study of 1,076 sexual assault cases,
20% were attacked by multiple assailants, 39% were assaulted
by strangers, 83% of females were vaginally penetrated, and
17% overall were sodomized. Genital trauma was documented
in 53% of those assaulted, and sperm or semen was detected
in 48% (120). In another study, in which toluidine blue dye
was used as an adjunct to naked-eye examination, 40% of
assaulted women (70% of nulliparas) had detectable vaginal
lacerations, compared with 5% of women examined after con-
sensual sex (121).
Despite these risks and the establishment of multidisciplinary
support services, sexual assault survivors often decline nPEP,
and many who do take it do not complete the 28-day course.
This pattern has been reported in several countries and sev-
eral programs in North America. In Vancouver, 71 of 258
assault survivors accepted the 5-day starter pack of nPEP, 29
returned for additional doses, and eight completed 4 weeks of
therapy (96). Those with the highest risk for HIV exposure
(i.e., source known to be HIV infected, a homosexual or bi-
sexual man, or an injection-drug user) were more likely to
begin and complete nPEP.
Patients who have been sexually assaulted will benefit from
supportive services to improve adherence to nPEP if it is pre-
scribed, and from psychological and other support provided
by sexual assault crisis centers. All sexually assaulted patients
should be tested and administered prophylaxis for sexually
transmitted infections (85), and women who might become
pregnant should be offered emergency contraception (122).
Inmates
Certain illegal behaviors that result in imprisonment (e.g.,
prostitution and injection-drug use) also might be associated
with a higher prevalence of HIV infection among prison
inmates than among the general population (119). However,
studies indicate that the risk for becoming infected in prison
is probably less than the risk outside prison (122–125). How-
ever, when exposure does occur, because sexual contact and
injection-drug use are prohibited in jails and prisons, prison-
ers who have experienced such exposures might be unable or
unwilling to report the behaviors to health-care providers.
Administrators and health-care providers working in cor-
rectional settings should develop and implement systems to
make HIV education and risk-reduction counseling, nPEP,
voluntary HIV testing, and HIV care confidentially available
to inmates. Such programs will allow inmates to benefit from
nPEP when indicated, facilitate treatment services for those
with drug addiction, and assist in the identification and treat-
ment of sexual assault survivors.
Injection-Drug Users
A history of injection-drug use should not deter clinicians
from prescribing nPEP if the exposure provides an opportu-
nity to reduce the risk for consequent HIV infection. A sur-
vey of clinicians serving injection-drug users determined a high
degree of willingness to provide nPEP after different types of
potential HIV exposure (126).
In judging whether exposures are isolated, episodic, or
ongoing, clinicians should consider that persons who con-
tinue to engage in risk behaviors (e.g., commercial sex work-
ers or users of illicit drugs) might be practicing risk reduction
(e.g., using condoms with every client, not sharing syringes,
and using a new sterile syringe for each injection). Therefore,
a high-risk exposure might represent an exceptional occur-
rence for such persons despite their ongoing risk behavior.
Injection-drug users should be assessed for their interest in
substance abuse treatment and their knowledge and use of
safe injection and sex practices. Patients desiring substance
abuse treatment should be referred for such treatment. Per-
sons who continue to inject or who are at risk for relapse to
injection-drug use should be instructed in the use of a new
sterile syringe for each injection and the importance of avoid-
ing the sharing of injection equipment. In areas where pro-
grams are available, health-care providers should refer such
patients to appropriate sources of sterile injection equipment.
Conclusion
Accumulated data from animal and human clinical and
observational studies demonstrate that antiretroviral therapy
initiated as soon as possible within 48–72 hours of sexual,
injection-drug–use, and other substantial nonoccupational
HIV exposure and continued for 28 days might reduce the
likelihood of transmission. Because of these findings, DHHS
recommends the prompt initiation of nPEP with HAART
when persons seek care within 72 hours after exposure, the
source is known to be HIV infected, and the exposure event
presents a substantial risk for transmission. When the HIV
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status of the source is not known and the patient seeks care
within 72 hours after exposure, DHHS does not recommend
for or against nPEP but encourages clinicians and patients to
weigh the risks and benefits on a case-by-case basis. When the
transmission risk is negligible or when patients seek care >72
hours after a substantial exposure, nPEP is not recommended;
however, clinicians might consider prescribing nPEP for
patients who seek care >72 hours after a substantial exposure
if, in their judgment, the diminished potential benefit of nPEP
outweighs the potential risk for adverse events from
antiretroviral medications. These recommendations are
intended for the United States and might not apply in other
countries.
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Goal and Objectives
This MMWR describes the potential risks and benefits of antiretroviral postexposure prophylaxis after nonoccupational exposures to human immunodeficiency virus
(HIV). These recommendations were developed by CDC staff in collaboration with scientists, public health officials, clinicians, ethicists, members of affected
communities, and representatives from professional associations and industry. The goal of this report is to provide information on which to base decisions regarding
postexposure prophylaxis after a nonoccupational exposure to HIV. After completing this educational activity, the reader should be able to 1) describe the
characteristics of a potential HIV exposure; 2) describe situations in which postexposure prophylaxis is most likely to be beneficial; 3) describe sources for obtaining
information on antiretroviral regimens; and 4) describe appropriate follow-up schedules for persons who are prescribed antiretroviral postexposure prophylaxis.
To receive continuing education credit, please answer all of the following questions.
1. Evidence from controlled studies among humans indicates that the
administration of antiretroviral postexposure prophylaxis after




2. On the basis of available evidence from animal studies, antiretroviral
postexposure prophylaxis is most likely to be beneficial when initiated
as soon as possible after exposure, and in the majority of cases, should




D. None of the above.
3. Contact of which of the following body sites with HIV-infected bodily





E. A and D are correct.
F. A, B, and D are correct.
4. In a person with HIV infection, potentially infectious fluids include all
of the following, except . . .
A. blood.
B. saliva visibly contaminated with blood.
C. urine not visibly contaminated with blood.
D. genital secretions.
E. none of the above; all are potentially infectious.
5. Which of the following lists of exposure types are correctly ordered
from greatest risk of infection to least risk of infection?
A. Insertive anal is greater than insertive oral, which is greater than
insertive vaginal.
B. Receptive anal is greater than receptive vaginal, which is greater than
receptive oral.
C. Insertive anal is greater than receptive anal, which is greater than
receptive oral.
D. None of the above.
6. The recommended duration of antiretroviral postexposure




D. none of the above.
7. Antiretroviral medications that should be avoided for pregnant




D. stavudine (D4T) in combination with didanosine (ddI).
E. A, B, and D.
8. Patients who are prescribed antiretroviral postexposure prophylaxis
should be instructed about the symptoms of acute retroviral infection,




D. all of the above.
E. B and C only.
9. Follow-up visits and testing of persons who are prescribed
antiretroviral postexposure prophylaxis should be performed at




D. all of the above.
10. In addition to HIV antibody testing, follow-up laboratory testing of
persons who are prescribed antiretroviral postexposure prophylaxis
should include . . .
A. hepatitis A serology.
B. hepatitis B serology.
C. hepatitis C serology.
D. complete blood count, blood urea nitrogen/creatinine, and hepatic
enzymes.
E. all of the above.
F. B, C, and D.






12. I plan to use these recommendations as the basis for . . . (Indicate all
that apply.)
A. health education materials.
B. insurance reimbursement policies.
C. local practice guidelines.
D. public policy.
E. other.





























































































































































































































































































































































































































































































































































































































































































































































































































































































13. Each month, approximately how many patients with a potential HIV







14. How much time did you spend reading this report and completing the
exam?
A. <2.0 hours.
B. >2.0 hours but <3.0 hours.
C. >3.0 hours but <4.0.
D. >4.0 hours.
15. After reading this report, I am confident I can describe the
characteristics of a potential HIV exposure.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
16. After reading this report, I am confident I can describe situations in
which postexposure prophylaxis is most likely to be beneficial.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
17. After reading this report, I am confident I can describe sources for
obtaining information on antiretroviral regimens.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
18. After reading this report, I am confident I can describe appropriate




C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
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Correct answers for questions 1–10.
1. B. 2. A. 3. F. 4. C. 5. B. 6. C. 7. E. 8. D. 9. D. 10. F.
19. The objectives are relevant to the goal of this report.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.




C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.




C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
22. These recommendations will affect my practice.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
23. The content of this activity was appropriate for my educational needs.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
24. The availability of continuing education credit influenced my
decision to read this report.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
25. How did you learn about this continuing education activity?
A. Internet.
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